0001209191-20-055041.txt : 20201016 0001209191-20-055041.hdr.sgml : 20201016 20201016154955 ACCESSION NUMBER: 0001209191-20-055041 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201014 FILED AS OF DATE: 20201016 DATE AS OF CHANGE: 20201016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Loven Jakob CENTRAL INDEX KEY: 0001753644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39592 FILM NUMBER: 201243940 MAIL ADDRESS: STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK STREET 2: 395 WINCHESTER AVENUE CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kronos Bio, Inc. CENTRAL INDEX KEY: 0001741830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: 212-871-7920 MAIL ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-14 0 0001741830 Kronos Bio, Inc. KRON 0001753644 Loven Jakob C/O KRONOS BIO, INC. 1300 SO. EL CAMINO REAL, SUITE 300 SAN MATEO CA 94402 1 0 0 0 Common Stock 2020-10-14 4 C 0 1376313 A 1376313 I See footnote Common Stock 2020-10-14 4 C 0 169031 16.15 A 1545344 I See footnote Series A Preferred Stock 2020-10-14 4 C 0 1304563 D Common Stock 1376313 0 I See footnote Convertible Promissory Note 16.15 2020-10-14 4 C 0 2729859.81 0.00 D 2022-02-20 Common Stock 169031 0 I See footnote Each share of Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. The securities are held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. /s/ David Tanen, Attorney-in-Fact 2020-10-16